Viking Therapeutics released new maintenance-phase data on September 22, 2026 for VK2735, its injectable GLP-1/GIP dual agonist, showing that participants who had already lost weight on the drug were able to hold onto most of that loss even when dosed less frequently. The market reaction was immediate: Viking's stock (VKTX) surged more than 30% in premarket trading that morning, changing hands around $39.42.

What the Data Showed

The study examined what happens after an initial weight-loss phase, when patients are shifted to reduced-frequency dosing schedules rather than stopping treatment altogether. According to the company's reported figures, participants who moved to an every-other-week dosing schedule retained up to 97% of the weight they had already lost. Those shifted to monthly dosing retained up to 90%. By comparison, participants who were switched to placebo retained only about 61% of their prior weight loss, illustrating the substantial weight regain that tends to occur once GLP-1/GIP therapy is stopped entirely.

Why a Maintenance Study Matters

Most of the headline data reported for GLP-1-class drugs, on this site and elsewhere, describes how much weight participants lose during an initial treatment phase, typically with weekly injections. Far less has been published on what happens afterward, once someone has reached a goal and clinicians and patients start asking whether the same result can be maintained with fewer injections. If confirmed in further trials, a drug that can preserve most of its effect on a monthly or twice-monthly schedule would represent a meaningful practical and adherence advantage over weekly dosing, since fewer injections generally means an easier regimen to sustain long-term.

Where VK2735 Stands Today

VK2735 is not an FDA-approved medication. It remains an investigational compound, currently advancing through Phase 3 obesity trials, with both injectable and oral formulations in development. Nothing about this maintenance data changes that regulatory status, and the figures reported are company-disclosed trial results that have not yet appeared in a peer-reviewed publication or been independently reviewed by the FDA. As with any drug-development announcement, the numbers describe a specific trial population under trial conditions, and it is common for effect sizes to shift somewhat as data mature and undergo full statistical review.

The Bigger Picture

Viking is one of several companies, alongside Eli Lilly, Novo Nordisk, and others tracked on this site, competing to bring next-generation multi-agonist peptides to market. Questions about dosing frequency and long-term maintenance are becoming a bigger part of that competition as the first wave of weekly injectables matures and companies look for ways to differentiate on convenience as well as efficacy. Investors and patients alike should keep in mind that until VK2735 completes Phase 3 development and receives FDA review, it is not available as an approved treatment, and any product marketed under that name outside of clinical trials would not be a legitimate, regulated medication.

What to Watch Next

Viking has said fuller results from the maintenance study, including additional detail on the trial's design and statistical analysis, are expected to be presented at an upcoming medical conference and eventually submitted for peer review. Until then, today's figures should be read as an early, company-reported signal rather than a finalized result. For patients and clinicians following the GLP-1/GIP category, the more interesting long-term question may not be which drug produces the largest initial weight loss, but which ones can sustain results with the fewest injections and the least treatment burden over time.